• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.02
  • VXN 16.95
  • VXO 14.44
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

Company Profile

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The company has progressed two compounds into late-stage pivotal clinical trials comprising Peramivir, an anti-viral for influenza; and Forodesine, a purine nucleoside phosphorylase (PNP) inhibitor forcutaneous T-cell lymphoma (CTCL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the United States Department of Health and Human Services (HHS). Forodesine has been granted Orphan Drug status by the FDA for three indications, including T-cell non-Hodgkin's lymphoma, including CTCL; CLL and related leukemias, such as T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for the treatment of B-ALL. BioCryst Pharmaceuticals is also testing BCX-4208, a second generation PNP inhibitor, which is in a Phase II study for the treatment of gout. The company utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. It has strategic alliances with the U.S. Department of Health and Human Services; Shionogi & Co., Ltd.; Green Cross Corporation; and Mundipharma International Holdings Limited. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is based in Birmingham, Alabama.

BCRX (BioCryst Pharmaceuticals Inc)
Last Trade 2.81 Date 1/24/2020
Change % -6.34 % Price Change -0.19
Open 3.0 52 Week High 9.95
High 3.03 52 Week Low 1.38
Low 2.71 Type stock
Volume 4905252 Average Volume 3354175
Prev Close 3.0 Stock Exchange NASDAQ
Bid 2.85 Ask 2.88
Bid Size 36 Ask Size 1
1st Yr Estimated EPS Growth -0.2101 2nd Yr Estimated EPS Growth -0.2461
2 Years Forward Earning Yield -0.2562 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share -0.2678 Book Value Yield -0.0953
Buy Back Yield 0.0 CAPE Ratio
Cash Return -0.2055 Cash Flow per Share -0.9358
Cash Flow Yield -0.333 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.4306 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue 12.0282 EV / Pre Tax Income
EV / Revenue 37.925 EV / Total Asset 4.9613
Expected Dividend Growth Rate Free Cash Flow per Share -0.9391
Free Caash Flow Ratio Free Cash Flow Yield -0.3342
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.3399 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio PB Ratio 10 Year Growth
PB Ratio 3 Year Growth 16.921442 Cash Ratio 3 Year Average 601.8766
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 0.814493
Price to Cash Ratio 6.3258 Price / EBITDA
Price to Sales Ratio 26.156035 Price to Sales Ratio 10 Year Growth 0.220737
Price to Sales Ratio 3 Year Avg 22.883532 Price to Sales Ratio 5 Year Avg
Sale per Share 0.1074 Sales Yield 0.0382
Sustainable Growth Rate -8.4571 Tangible Book Value per Share -0.2678
Tangible Book Value per Share 3 year Avg 0.4723 Tangible Book Value per Share 5 year Avg 0.4688
Total Asset per Share 0.5874 Total Yield 0.0
Working Capital per Share -0.0218 Working Capital per Share 3 Year Avg 0.5465
Working Capital per Share 5 Year Avg 0.4181 Beta 1.690068